Loading…
Employees: 2,946
Size Maccura Biotechnology (300463.SZ) is a China Health Care company (Medical Specialties) with a market value of $814M, the 2713th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.06 on 6 Nov 2026.
Performance Over six months the shares fell 13.6%, against -7.2% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 1.3% over the last twelve months (peer median +15.3%); the operating margin is -3.6% (peer median 11.4%).
Valuation It trades at 164.7× forward earnings against a peer median of 19.5× (most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points below its cost of capital (6.3% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.18B | CN¥2.15B | CN¥2.53B | CN¥2.88B | CN¥3.59B |
| Revenue growth | — | -15% | -12% | -20% | — |
| Gross profit | CN¥1.35B | CN¥925M | CN¥1.10B | CN¥1.31B | CN¥1.71B |
| EBITDA | n/a | CN¥338M | CN¥584M | CN¥636M | CN¥1.09B |
| Net income | -CN¥32.9M | -CN¥35.8M | CN¥127M | CN¥313M | CN¥708M |
| Free cash flow | CN¥208M | -CN¥147M | -CN¥326M | CN¥34.2M | -CN¥133M |
| Capital expenditure | CN¥562M | CN¥749M | CN¥963M | CN¥878M | CN¥988M |
| Total debt | CN¥842M | CN¥977M | CN¥789M | CN¥746M | CN¥703M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300463.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.8% | -4.4% | 11th highest of 21 |
| 6-month return | -13.6% | -7.2% | 7th lowest of 21 |
| Distance from 52-week high | -36.2% | -28.7% | 8th lowest of 21 |
| Revenue growth (TTM) | -1.3% | +15.3% | 4th lowest of 21 |
| Operating margin | -3.6% | 11.4% | 5th lowest of 21 |
| Forward P/E | 164.7× | 19.5× | most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 9.2% | 0.1% | 4th most demanding of 12 |
| Growth delivered (Del g) | -10.2% | +15.6% | lowest of 12 |
| Hurdle (Req g minus delivered) | +19.3 pp | -18.0 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | -3.4 pp | +0.8 pp | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 164.7× | 9.2% | -10.2% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 30.0× | 21.1% | +24.2% |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | n/a | n/a | n/a |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | n/a | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 12.5× | -8.0% | +6.6% |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | n/a | n/a | n/a |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 17.8× | -2.1% | +23.5% |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 20.3× | n/a | n/a |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 19.8× | 0.1% | +15.6% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 10.1× | -10.5% | +12.4% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | n/a | n/a | n/a |